Zobrazeno 1 - 10
of 454
pro vyhledávání: ''
Autor:
Yuri Gorelik, Sigal Pressman, S Greenfeld, Nathan Lederman, Chagit Friss, Naama Geva-Zatorsky, Yechezkel Kashi, Yehuda Chowers, Alexandera Blatt, Revital Kariv, Shay Freilich, G Focht, Shiran Gerassy-Vainberg, Yiska Loewenberg Weisband, Shai S. Shen-Orr, Iris Dotan
Publikováno v:
Gut
ObjectiveAnti-drug antibodies (ADA) to anti-tumour necrosis factor (anti-TNF) therapy drive treatment loss of response. An association between intestinal microbial composition and response to anti-TNF therapy was noted. We therefore aimed to assess t
Publikováno v:
Annals of the Rheumatic Diseases. 80:1393-1399
BackgroundHepatitis B surface antigen (HBsAg) reverse seroconversion (RS) can happen in patients with rheumatoid arthritis (RA) with resolved hepatitis B (RHB) undergoing biological disease-modifying antirheumatic drugs (bDMARDs). But the incidence a
Publikováno v:
Gut
ObjectiveOur aim was to explore the risk of infection with all classes of inflammatory bowel disease (IBD) medications and the impact of these medications on the disease course in a nationwide cohort of patients with IBD.DesignThis was a retrospectiv
Autor:
Fay Louise Murray-Brown
Publikováno v:
BMJ Supportive & Palliative Care. 11:217-225
BackgroundCholestatic itch is caused by intrahepatic liver diseases, such as primary biliary cirrhosis and extrahepatic obstruction of the biliary tree, often caused by tumours. The pathophysiology of cholestatic itch is complex and no single treatme
Publikováno v:
Frontline Gastroenterol
Acute severe ulcerative colitis (ASUC) is a medical emergency which is associated with significant morbidity and a mortality rate of 1%. ASUC requires prompt recognition and treatment. Optimal management includes admission to a specialist gastrointes
Publikováno v:
European Journal of Hospital Pharmacy. 29:e91-e94
Piperacillin-tazobactam is a broad-spectrum antimicrobial agent that is commonly used in clinical practice. The development of delayed drug hypersensitivity reaction (DHR) has been reported in several cases previously. Here we describe an unusual cas
Autor:
Catherine Luedke, Jerald Z. Gong, Lian-He Yang, Yue Zhao, Rachel Jug, Jenna McCracken, Jonathan Galeotti, Jake Maule, Imran Siddiqi, Endi Wang, Chuanyi M. Lu
Publikováno v:
Journal of Clinical Pathology. 75:292-301
AimsMyeloid neoplasms occur in the setting of chronic lymphocytic leukaemia (CLL)/CLL-like disease. The underlying pathogenesis has not been elucidated.MethodsRetrospectively analysed 66 cases of myeloid neoplasms in patients with CLL/CLL-like diseas
Autor:
Ying Wang, Arlene M. Correa, Boyi Gan, Randy L. Johnson, Ailing W. Scott, Cordelia Y Li, Melissa Pool Pizzi, Jeannelyn S. Estrella, Longfei Huo, Shaozhong Wei, Lianchun Xiao, Brian Weston, Namita Shanbhag, Shumei Song, Yuan Li, Wayne L. Hofstetter, Guang Lei, Lang Ma, Jaffer A. Ajani, Manoop S. Bhutani, Bin Liu, Jeffrey H. Lee, Qiongrong Chen, Jiankang Jin
Publikováno v:
Gut
ObjectiveGastro-oesophageal cancers (GEC) are resistant to therapy and lead to poor prognosis. The cancer stem cells (CSCs) and antiapoptotic pathways often confer therapy resistance. We sought to elucidate the antitumour action of a BCL-2 inhibitor,
Autor:
Neelufar Mozaffarian, Daniel W. T Ching, Jonathan Kay, Z. Yin, Rene Westhovens, Chantal Tasset, John S. Sundy, Robert Landewé, Gerd R Burmester, Tatsuya Atsumi, William Stohl, Franziska Matzkies, Désirée van der Heijde, William F. C. Rigby, Osvaldo D. Messina, Arvind Chopra, Ying Guo, Beatrix Bartok, Angelika Jahreis
Publikováno v:
Annals of the Rheumatic Diseases
Objectives To investigate efficacy and safety of the Janus kinase-1 inhibitor filgotinib in patients with active rheumatoid arthritis (RA) with limited or no prior methotrexate (MTX) exposure. Methods This 52-week, phase 3, multicentre, double-blind
Publikováno v:
Gut. 70:2076-2084
ObjectiveIn treating patients with inflammatory bowel disease (IBD), how concomitant medications influence the response to infliximab is largely unexplored. We aim to evaluate whether proton pump inhibitors (PPIs) affect the response to infliximab th